Jasmine Zain, MD

Articles by Jasmine Zain, MD

At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.

What Were the Key Hematologic Oncology Takeaways from SOHO 2026?

ByJasmine Zain, MD,David Sallman, MD,Julie M. Vose, MD, MBA

September 21st 2026

At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.

Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment selection.

Screening for CHIP Mutations to Guide CAR T-Cell Candidacy in Lymphoma

ByJasmine Zain, MD

September 19th 2026

Jasmine Zain, MD, described how preexisting CHIP mutations should inform preinfusion risk counseling and treatment selection.

Jasmine Zain, MD, described the molecular workup to determine whether a secondary malignancy after CAR T-cell therapy reflects direct insertional mutagenesis.

Differentiating Mutagenesis From Genotoxic Risk in Secondary Malignancies

ByJasmine Zain, MD

September 17th 2026

Jasmine Zain, MD, described the molecular workup to determine whether a secondary malignancy after CAR T-cell therapy reflects direct insertional mutagenesis.

At SOHO 2026, Jasmine Zain, MD, discussed communicating the FDA’s boxed warning for secondary malignancies post–CAR T-cell therapy to patients.

Communicating CAR T Secondary Malignancy Risks in Hematologic Oncology

ByJasmine Zain, MD

September 10th 2026

At SOHO 2026, Jasmine Zain, MD, discussed communicating the FDA’s boxed warning for secondary malignancies post–CAR T-cell therapy to patients.

Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice-PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma

ByNatalia Pin Chuen Zing, MD, MSc,Thais Fischer, MD,Jasmine Zain, MD,Massimo Federico, MD,Steven T. Rosen, MD

August 15th 2018

In Part 2 of this two-part series, this review covers extranodal natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma.

Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice-PART 1: PTCL-NOS, FTCL, AITL, ALCL

ByNatalia Pin Chuen Zing, MD, MSc,Thais Fischer, MD,Jasmine Zain, MD,Massimo Federico, MD,Steven T. Rosen, MD

July 15th 2018

This two-part series highlights the most important aspects of PTCLs and describes current treatment options and investigative opportunities. Part 1 will cover PTCL not otherwise specified, follicular T-cell lymphoma, angioimmunoblastic T-cell lymphoma, anaplastic large-cell lymphoma (ALCL), and breast implant–associated ALCL.

An Elderly Man With New Skin Plaques Consistent With Cutaneous T-Cell Lymphoma

ByBelén Rubio-González, MD,Jasmine Zain, MD,Steven T. Rosen, MD,Christiane Querfeld, MD, PhD

October 15th 2016

An 80-year-old man presented with a disabling pruritic rash characterized by disseminated and coalescing plaques on the trunk and proximal extremities and covering 40% of his total body surface area, without peripheral lymphadenopathy.